Literature DB >> 12816917

Comprehensive UGT1A1 genotyping in a Japanese population by pyrosequencing.

Mayumi Saeki1, Yoshiro Saito, Hideto Jinno, Masahiro Tohkin, Kouichi Kurose, Nahoko Kaniwa, Kazuo Komamura, Kazuyuki Ueno, Shiro Kamakura, Masafumi Kitakaze, Shogo Ozawa, Jun-Ichi Sawada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12816917     DOI： 10.1373/49.7.1182

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


× No keyword cloud information.
  10 in total

1.  High-throughput single-base mismatch detection for genotyping of UDP-glucuronosyltransferase (UGT1A1) with probe capture assay coupled with modified allele-specific primer extension reaction (MASPER).

Authors:  Osamu Kisaki; Seiji Kato; Kohei Shinohara; Hisahide Hiura; Tomohiro Samori; Hiroshi Sato
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

2.  Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.

Authors:  Shouji Shimoyama
Journal:  World J Gastrointest Surg       Date:  2010-01-27

3.  Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.

Authors:  Crystal S Denlinger; Rebecca Blanchard; Lu Xu; Coen Bernaards; Samuel Litwin; Cynthia Spittle; Daniel J Berg; Susan McLaughlin; Maryann Redlinger; Andrew Dorr; Julie Hambleton; Scott Holden; Anne Kearns; Sara Kenkare-Mitra; Bert Lum; Neal J Meropol; Peter J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  2009-05-05       Impact factor: 3.333

4.  Comparison of effects of UGT1A1*6 and UGT1A1*28 on irinotecan-induced adverse reactions in the Japanese population: analysis of the Biobank Japan Project.

Authors:  Keiko Hikino; Takeshi Ozeki; Masaru Koido; Chikashi Terao; Yoichiro Kamatani; Yoshinori Murakami; Michiaki Kubo; Taisei Mushiroda
Journal:  J Hum Genet       Date:  2019-10-04       Impact factor: 3.172

5.  Multiplex pyrosequencing assay using AdvISER-MH-PYRO algorithm: a case for rapid and cost-effective genotyping analysis of prostate cancer risk-associated SNPs.

Authors:  Jérôme Ambroise; Valentina Butoescu; Annie Robert; Bertrand Tombal; Jean-Luc Gala
Journal:  BMC Med Genet       Date:  2015-06-25       Impact factor: 2.103

6.  Rapid detection of the irinotecan-related UGT1A1*28 polymorphism by asymmetric PCR melting curve analysis using one fluorescent probe.

Authors:  Xiaomu Kong; Ye Xu; Peng Gao; Yi Liu; Xuran Wang; Meimei Zhao; Yongwei Jiang; Hui Yang; Yongtong Cao; Liang Ma
Journal:  J Clin Lab Anal       Date:  2022-06-29       Impact factor: 3.124

Review 7.  Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.

Authors:  Glenn E Palomaki; Linda A Bradley; Michael P Douglas; Katherine Kolor; W David Dotson
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

8.  Pharmacogenomic assessment of Mexican and Peruvian populations.

Authors:  Sharon Marsh; Cristi R King; Derek J Van Booven; Jane Y Revollo; Robert H Gilman; Howard L McLeod
Journal:  Pharmacogenomics       Date:  2015       Impact factor: 2.533

9.  Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer.

Authors:  Minmin Li; Zhehai Wang; Jun Guo; Jie Liu; Changzheng Li; Lin Liu; Huan Shi; Liyan Liu; Huihui Li; Chao Xie; Xia Zhang; Wenwen Sun; Shu Fang; Xiang Bi
Journal:  Onco Targets Ther       Date:  2014-09-23       Impact factor: 4.147

10.  Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China.

Authors:  Lang Yi; Guigao Lin; Kuo Zhang; Lunan Wang; Rui Zhang; Jiehong Xie; Jinming Li
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.